The European Patent Office (EPO) has published patent application EP4493705A1, filed by Rutgers, the State University of New Jersey. The patent, titled "CONTROLLED MUSCLE-SPECIFIC GENE DELIVERY," was published on March 18, 2026, and covers various aspects of gene delivery technology, including specific IPC classifications related to gene delivery and cell culture.

This publication represents the grant of a patent, not a regulatory rule or guidance. For compliance officers, this means that the technology described is now protected intellectual property within the designated European states. No immediate compliance actions are required for regulated entities, but companies operating in the gene therapy or pharmaceutical space should be aware of this patent when developing or commercializing related technologies to avoid potential infringement.